Bupropion: Risks and advantages of its use. What preclinical research says;Bupropion: Risques et avantages de son utilisation. Que dit la recherche pré-clinique?

Annales de Medecine Interne

Volumn 153, Issue 7 SUPPL. 1, 2002, Pages

  Noble, Florence ^a  

^a Laboratoire de Pharmacochimie   (France)

Author keywords

Amphetamine; Bupropion; Dependence; Nicotine

Indexed keywords

AMFEBUTAMONE; NICOTINE;

ABSTINENCE; CIGARETTE SMOKING; DRUG MECHANISM; DRUG STRUCTURE; DRUG USE; HUMAN; MEDICAL RESEARCH; NICOTINE REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SMOKING CESSATION; TOBACCO DEPENDENCE;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; HUMANS; RISK FACTORS; SMOKING CESSATION;

EID: 0036868111     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Di Chiara G: Behavioural pharmacology and neurobiology of nicotine reward and dependence. In: Clementi F, FORNASARI D, Gotti C, eds. Handbook of Experimental Pharmacology. New York: Springer, 2000; 603-750.
2. Picciotto MR, Corrigall WA: Neuronal systems underlying behaviors related to nicotine addiction: Neural circuits and molecular genetics. J Neurosci, 2002; 22: 3338-41.
3. Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft Van Huijsduijnen R, Chiamulera C: Common neural substrates for the addictive properties of nicotine and cocaine. Science, 1997; 275: 83-6.
4. Cordero-Erausquin M, Marubio LM, Klink R, Changeux JP: Nicotinic receptor function: New perspectives from knockout mice. Trends Pharmacol Sci, 2000; 21: 211-7.
5. Picciotto MR, Zoli M, Rimondini R, et al.: Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature, 1998; 391: 173-7.
6. Fowler JS, Volkow ND, Wang GJ, et al.: Inhibition of monoamine oxidase B in the brains of smokers. Nature, 1996; 379: 733-6.
7. Linnér L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH: Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectivity increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther, 2001; 297: 540-6.
8. Bardo MT, Rauhut AS, Mullins SN, Dwoskin LP: Effect of reboxetine on nicotine self-administration and reinstatement: Preclinical evidence for a novel smoking cessation pharmacotherapy. Soc Neurosci Abstr, 2001; 31: 344.
9. Hayford KE, Patten CA, Rummans TA, et al.: Efficacy of bupropion for smoking cessation in smokers with a former history of major depression. Br J Psychiatr, 1999; 174: 173-8.
10. Ascher JA, Cole JO, Colin JN, et al.: Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatr, 1995; 56: 395-401.
11. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM: Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology, 1994; 11: 133-41.
12. Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA: Use of dopamine-β-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther, 2001; 298: 651-7.
13. Slemmer JE, Martin BR, Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther, 2000; 295: 321-7.
14. Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB: Metabolism of some "second"- and "fourth"-generation antidepressants: Iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol, 1999; 19: 427-42.
15. Zyban®. Product Information. GlaxoWellcome, 1999.
16. Desai HD, Seabolt J, Jann MW: Smoking in patients receiving psychotropic medications. A pharmacokinetic perspective. CNS Drugs, 2001; 15: 469-94.
17. Pelissolo A, Bouvard MP, Lecendreux M, MourenSimeoni MC: Psychostimulants. In: Encycl. Med. Chir. Psychiatrie. Paris: Elsevier, 1996.
18. Jones CN, Howard JL, McBennett ST: Stimulus properties of antidepressants in the rat. Psychopharmacology, 1980; 67: 111-8.
19. Rothman RB, Glowa JR: A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: Focus on GBR 12909. Mol Neurobiol, 1995; 11: 1-19.
20. Tella SR, Ladenheim B, Cadet JL: Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther, 1997; 281: 508-13.
21. Nielsen JA, Shannon NJ, Bero L, Moore KE: Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. Pharmacol Biochem Behav, 1986; 24: 795-9.
22. Zarrindast MR, Hosseini-Nia T: Anorectic and behavioural effects of bupropion. Gen Pharmacol, 1988; 19: 201-4.
23. McKearney JW: Effects of dopamine uptake inhibitors on schedule-controlled behavior in the squirrel monkey. Psychopharmacology, 1982; 78: 377-9.
24. Seiden LS, Dahms JL, Shaughnessy RA: Behavioral screen for antidepressants: The effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule. Psychopharmacology, 1985; 86: 55-60.
25. Sasaki-Adams D, Kelley AE: Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior. Neuropsychopharmacology, 2001; 25: 440-52.
26. Ortmann R: The conditioned place preference paradigm in rats: Effect of bupropion. Life Sci, 1985; 37: 2021-7.
27. Hoffmeister F, Goldberg SR: A comparison of chlorpromazine, imipramine, morphine, d-amphetamine self-administration in cocaine-dependent rhesus monkeys. J Pharmacol Exp Ther, 1973; 187: 8-14.
28. Lamb RJ, Griffiths RR: Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology, 1990; 102: 183-90.
29. Terry P, Katz JL: Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology, 1997; 134: 201-12.
30. Munzar P, Goldberg SR: Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology, 2000; 148: 209-16.
31. Katz JL, Izenwasser S, Terry P: Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology, 2000; 148: 90-8.
32. Miller L, Griffith J: A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers. Psychopharmacology (Berl), 1983; 80: 199-205.
33. Peck AW, Bye CE, Clubley M, Henson T, Riddington C: A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br J Clin Pharmacol, 1979; 7: 469-78.
34. Hamilton MJ, Smith PR, Peck AW: Effects of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electroencephalogram in healthy volunteers. Br J Clin Pharmacol, 1983; 15: 367-74.
35. Holm KJ, Spencer CM: Bupropion: A review of its use in the management of smoking cessation. Drugs, 2000; 59: 1007-24.
36. Rush CR, Kollins SH, Pazzaglia PJ: Discriminativestimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol, 1998; 6: 32-44.
37. Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, Deveaugh-Geiss J: Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res, 2001; 3: 131-40.